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ABSTRACT
The in-depth structure/function analysis of large
protein complexes, such as RNA polymerases
(RNAPs), requires an experimental platform capable
of assembling variants of such enzymes in large
numbers in a reproducible manner under defined
in vitro conditions. Here we describe a streamlined
and integrated protocol for assembling recombinant
archaeal RNAPs in a high-throughput 96-well
format. All aspects of the procedure including
construction of redesigned expression plasmids,
development of automated protein extraction/
in vitro assembly methods and activity assays
were specifically adapted for implementation on
robotic platforms. The optimized strategy allows the
parallel assembly and activity assay of 96 recombi-
nant RNAPs (including wild-type and mutant
variants) with little or no human intervention within
24h. We demonstrate the high-throughput potential
of this system by evaluating the side-chain require-
ments of a single amino acid position of the RNAP
Bridge Helix using saturation mutagenesis.
INTRODUCTION
Many of the enzymes involved in molecular information
processing are large and complex molecular machines that
are assembled from a variety of subunits. Recent technical
advances in X-ray crystallography have started to yield
insights into the structure of protein complexes, such as
bacterial and eukaryotic RNA polymerases (RNAPs;
1–6). RNAPs are key components of the cellular
transcriptional machineries. The availability of high-
resolution structures of such enzymes has inspired
numerous structural models attempting to explain key
RNAP functions in mechanistic terms. Some of these
models are based on features of individual structures
[e.g. separation of the transcript from the DNA template
strand (7)], whereas other mechanisms have been pro-
posed by comparing the conformations of protein
domains in diﬀerent crystals or by co-crystallizing poly-
merases in the presence of various substrates or cofactors
(e.g. 8,9). It is important to recognize that X-ray structures
can only provide individual ‘snap-shots’ of molecular
events likely to involve considerable conformational
changes and/or short-lived intermediates. Predictions
based on such static models must therefore be tested
extensively by targeted mutagenesis of key domains (and
individual residues therein) to assess their functional
contributions (10). We believe that archaeal transcription
systems, and speciﬁcally archaeal RNAPs, provide an
ideal testing ground for the development of high-
throughput experimental strategies to obtain comprehen-
sive insights into their structure/function space. Archaea
contain a single RNAP and a reduced set of basal
transcription factors that closely resemble the eukaryotic
core RNAPII transcriptional machinery (11). Technical
obstacles preventing the in vitro assembly of catalytically
active eukaryotic RNAPs were a key factor that originally
motivated us to develop a method for the assembly of
archaeal RNAPs from recombinant subunits (12). The
fully recombinant system resulting from these eﬀorts
reproduces faithfully all known aspects of archaeal in vitro
transcription systems, including promoter-directed trans-
cription and activator-stimulated transcription (12–15).
The availability of such recombinant in vitro trans-
cription systems sets the scene for the introduction of any
desired mutation into any position within an archaeal
RNAP by incorporating a suitably mutated subunit into
the in vitro assembly reactions. Here we describe an
integrated experimental strategy that takes full advantage
of these features of the recombinant archaeal RNAP
system and allows the formulation of a high-throughput
approach by combining eﬃcient mutagenesis with a highly
automated protein puriﬁcation/in vitro assembly process.
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in vitro assembly method to convert a long and complex
manual method into a streamlined and simpliﬁed auto-
mated procedure that is capable of producing and
assaying hundreds of individually assembled enzyme
variants per week.
MATERIALS AND METHODS
Re-engineered bacterial expression vectors fortargeted
mutagenesis
The original expression vectors for the RNA polymerase
subunits A0 and B00 from the euryarchaeal hyperthermo-
phile Methanocaldococcus jannaschii (mjA0 and mjB00,
respectively) were generated by subcloning the full-
length, PCR-generated open reading frames into pET21a
(12). For this study, the pET21a-mjA0 vector was modiﬁed
by replacing the N-terminal portion of the reading frame
(NdeI-AleI) with a synthetic gene fragment (GenScript)
encoding the identical amino acid sequence, but contain-
ing codons optimized for Escherichia coli expression and
with unique restriction enzyme targets ﬂanking the Zipper
and Lid encoding sequences. The C-terminal portion
(BstBI-BamHI) of pET21a-mjA0 was also replaced with a
synthetic gene fragment (GenScript) containing optimized
codons and unique restriction enzyme targets ﬂanking the
Bridge Helix. A similar modiﬁcation (replacement of the
BseYI-EcoRI fragment with a synthetic gene construct)
was carried out on pET21a-mjB00 to allow mutagenesis of
the Fork Loop domains. Further details/full sequences/
samples of the modiﬁed constructs are available from the
corresponding author on request.
Robotic platforms
All robotic manipulations described here were carried
out on either of the two Theonyx Liquid Performers
(Aviso Trade GmbH), equipped with an 8-tip pipetting
arm, separate gripper arm, barcode reader, vacuum
manifold, microplate shaker, thermocycler, microplate
reader, 96-well microdialyzer and E-Page facility
(Invitrogen) and an integrated microplate centrifuge.
Detailed descriptions of all robotic procedures, platform
layouts and specialized hardware modiﬁcations are avail-
able from the corresponding author upon request.
Bacterial growth and harvest
Single E. coli ‘Acella’ (EdgeBio) colonies containing
wildtype or mutant pET expression constructs were
inoculated into 1.5ml of autoinduction growth medium
(16; Novagen ‘Overnight Express’) containing 100mg/ml
ampicillin in a 24-deepwell plate. The plates were covered
with a ‘BugStopper’ venting capmat (Whatman), bar-
coded and incubated in a shaking incubator for 18h at
378C at 250r.p.m. The plates were then transferred to the
robotic platform (1–4 plates per run). After reading the
barcode, each plate was transferred to the robotic shaker
for 10s (to ensure an even cell suspension) before 10mlo f
each culture were transferred to a 96-well plate for
automatically measuring the cell density at 600nm (A600)
after a 1/10 dilution step. This step documents cultures
that either did not grow or failed to reach the expected
cell density.
Recombinant protein extraction
All procedures described subsequently were carried out on
the robotic platforms at room temperature. Nine hundred
microlitres of each bacterial expression culture were
transferred from the 24-well growth plates to a deﬁned
position in a 2.2ml 96-deepwell block and then lysed
directly, without prior centrifugation, by the addition of a
mixture of 100ml FastBreak reagent (Promega) and 2ml
Lysonase (Novagen). The lysates were mixed extensively
by repeated up- and down-pipetting and occasional
vortexing on the robotic microplate shaker at 5min
intervals for a total of 30min at room temperature.
Inclusion bodies were then separated from the lysate using
the robotic centrifuge (10min at 4700r.p.m;  2300g),
washed once with 950ml TG100 buﬀer (25mM Tris base;
192mM glycine; pH 8.9) by vigorous robotic pipetting
and plate shaking. To ensure complete automation of the
entire procedure we developed a custom-built microplate
decanter that automatically decants the supernatants
without disturbing the inclusion body pellets (R.O.J.W.,
unpublished data). After a further centrifugation/auto-
matic decanting step the washed inclusion bodies were
solubilized by the addition of 500ml of TG100 buﬀer
containing near-saturating urea (8.3M) by robotic pipet-
ting and plate shaking. We chose the TG buﬀer system to
provide a vast excess of free amino groups which would
compete for the carbamylation reactions that might occur
in the urea-containing in vitro assembly reactions (see
subsequently). The protein concentrations of the resulting
solubilized inclusion body preparations were measured by
mixing 10ml with 190ml Bicinchonic Acid (BCA) protein
assay reagent (Sigma) in a clear microplate and measuring
the absorption at 562nm after incubation at 378C for 2h.
Diﬀerent concentrations of bovine serum albumin (BSA)
dissolved in TG100/8.3M urea were set up at the same
time to establish a standard curve. Out of several other
assays tested, we found that the BCA assay performed
best in the presence of the high urea concentrations used
and gave an essentially linear read-out in the 0.1–10mg/ml
range. We previously used b-mercaptoethanol (15mM) in
all of our subunit puriﬁcation buﬀers (12), but this
compound interferes with the BCA assay and was
therefore omitted without any apparent loss of activity
of the recombinant subunits after in vitro assembly
(R.O.J.W., unpublished observations). Based on compar-
isons with the BSA standards and on the staining of the
puriﬁed subunits on gels we typically obtained 250mgo f
puriﬁed recombinant subunits from 900ml expression
culture with a standard deviation in the concentrations
of individual subunit preparations of less than  10%.
AutomaticassemblyofrecombinantRNAPsin96-wellformat
A commercially available 96-well microdialysis device
(Spectrum Laboratories) was installed on top of a Hi300N
magnetic stirrer (Hanna Instruments) positioned on the
robotic platform. The dialyzer position is fully accessible
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perspex lid was customized for handling by the gripper
(details available from the corresponding author). A
peristaltic pump (Watson Marlow Sci400) was calibrated
to deliver a ﬂow-rate of 1ml/min and switched on and oﬀ
under robotic control. In vitro assembly reactions were set
up in a total volume of 100ml per dialysis well and a
dialysis membrane with a 3K cut-oﬀ point was used for all
assemblies (Spectrum Laboratories; a narrow pore mem-
brane is required to prevent the smallest subunits from
leaking into the buﬀer chamber under denaturing condi-
tions). The concentrations of the various RNAP subunits
and subunit ratios were empirically determined to yield
recombinant RNAPs displaying the same speciﬁc activities
in non-speciﬁc and factor-dependent transcription assays
as previously described for the wild-type enzyme (12). For
the example shown here (mjA0 G825-X mutagenesis set),
90ml of a ‘Master Mix’ containing 3.2mgA 00, 4.2mgB 0,
6mgB 00, 7.2mg D, 8.7mg L, 6.5mgH ,5 mg N and 3mgP
were mixed with 10ml of the robotically puriﬁed mjA0
mutant subunit ( 12mg). The stoichiometric ratios of the
subunits required for optimal in vitro assembly most likely
reﬂect diﬀerences in the relative refolding eﬃciencies.
Under these conditions the subunits present in the
Master Mix (-A0) are rate-limiting in the assembly
reactions, thus ensuring that the added mutant mjA0
subunits are present in >2 molar excess. Any minor
variation in the concentrations of various mjA0 samples
is thus compensated for and does not aﬀect the amount
of assembled polymerase (the presence of excess mjA0 has
no detectable negative eﬀect on the eﬃciency of the
assembly reaction).
High-throughput transcription assays
The following procedures were carried out automatically
without human intervention. Non-speciﬁc transcription
assays (measuring the incorporation of a-
32P-rUTP into
acid insoluble transcripts) were set up as 50ml reactions in
a 96-well thin wall plate using reaction conditions
previously described (12,14). After incubation for 45min
at 708C (using the integrated thermocycler with heated lid)
the plate was transferred to a temperature-regulated block
maintained at 18C. The precipitation of the radiolabelled
transcripts was initiated by the addition of 150ml 15% ice-
cold trichloroacetic acid (TCA), followed by incubation
for 30min at 18C. The precipitation reactions were then
transferred by pipetting onto a 96- GF/F glass ﬁber ﬁlter
plate (Whatman) positioned on the robotic vacuum
platform. The soluble portion of the reactions was ﬁltered
to waste. The precipitates immobilized on the ﬁlter surface
were washed eight times with 200ml ice-cold 10% TCA to
remove traces of unincorporated nucleotides, twice with
200ml ice-cold 95% ethanol and then dried by a ﬁnal
application of vacuum. The incorporated a-
32P-rUTP
levels were measured after addition of 50ml of scintillant
(Optiﬂuor-O) on a microplate counter (TopCount NXT,
Packard) and were found to be identical to the results
obtained with the previously described manual technique
(12,14).
RESULTS
Expression vector redesign
Structural studies of RNAPs have revealed that only a
relatively small proportion of amino acid residues are
likely to play any direct functional role in transcription
mechanisms. These residues are typically arranged within
structurally distinct domains [such as Fork Loops, Bridge
Helix, Lid, Zipper, Rudder (2,3)] that contact substrates
(DNA, RNA, nucleotides) directly and/or interact with
other protein domains within the active site (1–4,7,8).
Residues located within such domains are thus prime
targets for site-directed mutagenesis projects. Moreover,
these functional domains tend to be either inherently
unstructured [e.g. Fork and Trigger Loops (2–4)] or are
part of ﬂexible a-helical structures [e.g. Bridge Helix (1,2)
and Trigger Loop (8)] so that single amino acid substitu-
tions are unlikely to interfere with subunit assembly or
overall stability of the enzyme.
The RNAP from the archaeon M. jannaschii (mjRNAP)
contains 12 diﬀerent subunits that are structurally and
functionally highly similar to their counterparts in
eukaryotic RNAPII (11,12). A high-throughput func-
tional analysis of a particular functional domain, such as
the Bridge Helix located in the archaeal A0 subunit,
requires an eﬃcient method for creating the desired
mutants, followed by a robust method for purifying the
mutated subunits in a highly reproducible manner. The
resulting puriﬁed mutant protein preparations then need
to be combined with a ‘master mix’ of all other essential
subunits and assembled into separate recombinant
RNAPs. Finally, the enzymes containing the mutated
subunits need to be assayed and compared to the wild-
type polymerase to assess the phenotypic consequence of
the introduced mutations.
We started the design of the high-throughput assembly
strategy by redesigning the previously used bacterial
expression vectors encoding the mjA0 and mjB00 subunits
(12). These two subunits include many of the identiﬁed
functional motifs surrounding the active site (mjA0:
Zipper, Lid, Rudder, Switch-2, Bridge Helix; mjB00: Fork
Loop 1, Fork Loop 2; Figure 1a). The redesigned
sequences were codon-optimized for optimal translation
eﬃciency in E. coli, and also contain unique 6- and 8-bp
target sites for restriction enzymes that ﬂank the nucleo-
tide sequences encoding the various functional motifs
(Figure 1b). The introduced restriction enzyme sites are
silent, i.e. encode the ‘wild-type’ primary amino acid
sequence of the encoded proteins. Cutting these modiﬁed
expression vectors with two restriction enzymes ﬂanking a
particular functional domain releases a short piece of
double-stranded DNA and allows this sequence to be
replaced by a double-stranded synthetic oligonucleotide
encoding the desired codon replacement(s) (Figure 1c).
Using this method, we have up to now successfully created
systematic substitution mutants in several RNAP motifs,
including Fork Loop 1 and 2, Lid, Zipper and the Bridge
Helix (L.T., D.T., H.C. and R.O.J.W., unpublished
results). Apart from the ease of creating a variety of
mutations, one of the main advantages of this method of
creating mutants is that it allows the saturation
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ing on the length of the chosen motif) without aﬀecting
any of the other regions outside the targeted area. This
mutagenesis strategy therefore oﬀers many advantages
over frequently used ‘shotgun’ mutagenesis methods, such
as error-prone PCR (17), by limiting the mutagenic
changes to distinct regions of an open reading frame.
High-throughputexpression andpurification of RNAP
subunitvariants
The previous section described an approach capable of
creating a broad range of mutations restricted to ‘func-
tional’ residues. The resulting bacterial expression vectors
encode recombinant RNAP subunits (mjA0 or mjB00) that
contain a variety of predetermined mutations in one or
more residues. This is, however, only the ﬁrst step of a
more complex procedure since the mutant subunits need
to be assembled in the presence of all other essential
subunits into an intact recombinant RNAP before the
functional consequences of a particular mutation can be
assessed. These robotically implemented procedures take
place in parallel (up to 96 independent puriﬁcation/
assemblies per run) to maximize consistency and to
create optimal conditions for functional comparisons.
In addition, the technical solutions outlined below take
full advantage of eﬀorts to miniaturize protein expression/
puriﬁcation methods and the extensive use of automation/
robotic capabilities. A ﬂowchart that summarizes the
entire sequence of expression/puriﬁcation procedures is
shown in Figure 2.
The need for processing a large number of expression
constructs resulting from the mutagenesis strategy
described above preclude the previously described meth-
ods of growth of bacterial cultures on a ‘preparative’ scale
(typically 0.5–2.0l), followed by sonication and chromato-
graphic puriﬁcation of the recombinant subunits (12).
Instead, by growing the constructs in 24-deepwell plates
containing autoinduction medium (16) we were routinely
able to obtain  250mg of recombinant wild-type or
mutant mjA0 and mjB00 subunits from 900ml overnight
cultures at a satisfactory level of purity using robotic
procedures. Brieﬂy, after transfer to a 96-deepwell culture
plate, 900ml of each bacterial expression culture were lysed
directly (i.e. without centrifugation) by the addition of a
detergent/lysozyme/nuclease mixture. Since the mjA0 and
mjB00 subunits form insoluble inclusion bodies they can be
puriﬁed from the lysate by robotic centrifugation and
automatic supernatant decanting. The retained inclusion
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Figure 1. Redesign of the bacterial expression vectors. (a) Schematic diagram of the redesigned coding regions of the mjA0 and mjB00 bacterial
expression vectors. The full-length open reading frames are shown with the codon-optimized sequences in light blue. The position of the sequences
encoding key functional RNAP domains are shown in color (Zipper, Lid, Rudder, Switch-2 in red, Bridge Helix in dark green and Fork Loops in
blue). The numbers refer to nucleotide positions. (b) Original and redesigned sequence encoding the Bridge Helix domain and surroundings (positions
2281-2550 in the mjA0 open reading frame). The original nucleotide sequence (as found in the M. jannaschii genome; 23) is shown on the top line with
the redesigned sequence (starting at the BstBI site) beneath. The silently introduced restriction sites ﬂanking various portions of the Bridge Helix-
encoding sequence are in red, whereas other sequence alterations that improve codon usage in E. coli are shown in light blue. The amino acid
sequence encoded is shown in single-letter code in black and the Bridge Helix primary sequence is highlighted in green. (c) Example of mutagenic
oligonucleotides for creating targeted substitutions in Bridge Helix residues mjA0-G825. The two strands are designed to hybridize to each other to
create a double-stranded ‘cassette’ bearing single-stranded extensions (shown in red) suitable for ligating into cloning vectors cleaved with suitable
restriction enzymes. The cassettes shown have been used to replace the wild-type Bridge Helix sequence between the SﬁI and SbfI sites (as shown in
panel B) with a sequence containing a single randomized codon (shown in purple; 18).
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ionic-strength buﬀer containing saturated urea. At this
stage, the mjA0 or mjB00 subunit preparations are >95%
pure and are ready for assembly into recombinant
RNAPs. The protein concentrations of the puriﬁed
subunits are automatically determined on the robot
using a colorimetric assay and, as an optional step the
proteins can be characterized further by high-throughput
electrophoresis (Supplementary Figure S1). The simplicity
of the automated procedure ensures an exceptionally high
degree of consistence in the quality and quantity of the
recombinant subunits prepared in this manner, thus
contributing greatly to the ability to compare the activities
of the recombinant RNAPs produced at the next stage.
High-throughput invitro assembly of recombinant RNAP
variants
Active archaeal RNAP can be reconstituted by mixing the
various subunits in appropriate ratios under denaturing
conditions (6M urea), followed by the time-controlled
removal of urea by dialysis against buﬀers containing
decreasing urea concentrations (12,15). The originally
described methods were time-consuming (because the
buﬀers were changed manually according to a strictly
deﬁned timetable) and low-throughput (parallel assembly
of only a few recombinant RNAP preparations per
experiment). In addition, variations in the assembly
conditions (e.g. due to diﬀerences in protein/buﬀer
preparations) contributed to poor quality control in such
procedures. We therefore introduced two signiﬁcant
technical changes aimed at increasing throughput and
reproducibility. First, we changed the dialysis set-up by
using a microdialyzer device on the robotic platform that
allows the in vitro assembly of up to 96 recombinant
RNAPs in parallel (Figure 3a). The dialysis wells on the
microdialyzer are arranged in the standardized 96-well
format that facilitates the robotic transfer of liquids in and
out of the dialysis block. Each well typically holds 100ml
of dialyzate that is separated from a lower communal
buﬀer chamber by a dialysis membrane. The communal
buﬀer chamber contains inlet and outlet ports that allow
dialysis buﬀer from an external supply to be pumped
through the chamber (Figure 3a). This is an important
consideration in light of the other modiﬁcation we made in
the procedure: instead of manual changes of dialysis buﬀer
to lower the urea concentration during the assembly
reaction we decided that the reproducibility of the
procedure could be improved substantially if the buﬀer
changes were carried out automatically (similar to an
independently developed method; 18). We therefore
modiﬁed the renaturation protocol by initially ﬁlling the
chamber with  200ml of buﬀer containing 6M urea. The
RNAP subunit mixtures are then robotically pipetted into
the wells and dialyzed against the 6M urea buﬀer. After
1h a pump is switched on under robotic control to pump
urea-free buﬀer into the chamber at a low rate (typically
1ml/minute). The urea-free buﬀer is immediately mixed
with the 6M urea buﬀer in the chamber by a magnetic
stirrer and excess liquid is allowed to drain through the
outlet port. This simple set-up therefore leads to a slow
and continuous dilution of the urea concentration in the
dialysis buﬀer in the lower chamber, resulting in a
corresponding drop of the urea concentration in the
RNAP subunit mixtures located across the dialysis
membrane. Over a period of around 16–17h the urea
concentration in the dialysis chamber approaches zero and
the assembly reaction is complete (Figure 3b). The
assembled recombinant RNAPs are robotically pipetted
out of the dialysis wells and transferred to 96-well
microplates for immediate use in various functional
assays. The robotic systems carrying out these procedures
thus constitute a genuine ‘RNA polymerase factory’
capable of purifying and assembling up to 96 recombinant
archaeal multi-subunit complexes with little or no human
intervention.
Case study:saturation mutagenesis of mjA’-G825
We demonstrate the eﬀectiveness, reproducibility and
high-throughput potential of the RNA polymerase factory
strategy by showing examples of results obtained by
saturation mutagenesis of a single residue of the Bridge
Helix of archaeal RNAP. Brieﬂy, the Bridge Helix is a
highly conserved structure (Figure 4a) spanning the cleft
near the active site in bacterial, archaeal and eukaryotic
multi-subunit RNAPs (1–4). It is thought to play an
important (though still controversial) role during the
RNAP transcription cycle by deﬁning the position of
the template strand and of the DNA/RNA hybrid in the
Functional Assays
α-32P-rUTP incorporation
intoTCA-insoluble precipitate
96-well In Vitro Assembly
High-Throughput Dialysis
Inclusion Body Purification
Automatic centrifugation and
supernatant removal
Protein Extraction
FastBreak/Lysonase
Expression Cultures
24-Deepwell Plates
Autoinduction Medium
Cell Density Quantitation
A600 Measurement
Protein Quantitation
Bicinchonic acid assay
High-throughput Electrophoresis
E-PAGE48 and E-PAGE9
STAGE 1
STAGE 2
STAGE 3
Figure 2. Flow diagram of the automated subunit puriﬁcation and
assembly process. See text for further details.
Nucleic Acids Research,2008, Vol. 36,No. 1 249catalytic site (Figure 4b). Inspection of the yeast RNAPII
X-ray structure of an elongation complex (7; PDB #1SFO)
suggests that an evolutionary invariant residue (scRPB1-
G835 in yeast RNAPII, orthologous to mjA0-G825 in
M. jannaschi; Figure 4a) may have been speciﬁcally
selected for the small size of its side chain to allow an
unimpeded passage of the DNA template strand into the
active site. The available structural data predicts that any
other amino acid substitutions in this particular location
would result in decreased catalytic activity due to steric
clashes between the larger side chains and the phospho-
diester backbone of the DNA template strand. To test this
hypothesis we created a set of mjA0 mutants containing all
19 possible amino acid substitutions (the ‘mjA0 G825-X’
set) by substituting the SﬁI-SbfI fragment of the rede-
signed mjA0 expression vector with a double-stranded
synthetic oligonucleotide containing a randomized codon
(19) in the position encoding G825 (Figure 1c). A
complete set of amino acid substitutions in G825 was
selected from  60 randomly picked clones and by cloning
double-stranded oligonucleotides designed to contain any
missing substitutions. Plasmids encoding the mjA0 G825-X
subunit variants were grown in expression strains and
processed by the RNA polymerase factory. The results
obtained conﬁrm that the size of the side chain does
indeed appear to play a key role for the residue at position
825 (Figure 4c). The activities of recombinant RNAPs
containing the other 19 possible residues in this position
reach at the most 40% of the wild-type catalytic activity
and many of the more bulky amino acid substitutions
(F, Y, W, K, R, H) result in <5% activity in non-speciﬁc
transcription assays. The wide dynamic range of repro-
ducible activity measurements demonstrated by the mjA0
G825-X mutant set show that the RNA polymerase
factory is a robust experimental tool capable of providing
functional data at an unprecedented speed and accuracy.
DISCUSSION
The ability to routinely produce and assay up to 96
recombinant RNAPs within 24h in a highly automated
manner has many advantages. The most obvious advan-
tage is that this system is capable of testing sample
numbers that exceed the capability of most human
laboratory workers, especially if carried out on a
continuous basis over longer periods. The increased
throughput translates into an ability to screen a larger
number of mutants (e.g. a library of random mutants
spread over a large segment of a subunit) for particular
functional properties using a variety of automated assays.
Alternatively, the ability to process a substantial number
of samples can be used to measure the activity of a smaller
number of mutants with a high degree of accuracy by
increasing the amount of information available for
statistical analysis. In the examples shown here, it is
clear that a comparison of various mutant and wild-type
activities can be achieved with a high degree of accuracy
due to the optimized and robust design of the procedure.
A slightly less obvious (but in our view equally
important) key feature of the RNA polymerase factory
is that the robotic work ﬂow does not merely speed up a
particular subset of steps within a long protocol, but
actually encompasses the entire procedure. We have even
gone as far as eliminating a rather trivial human
intervention (decanting of supernatants from deep-well
plate after centrifugation) by constructing a custom-built
(a)( b)
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Figure 3. Robotic microdialysis set-up for assembly of recombinant RNAPs. (a) The photograph shows the placement of the 96-well microdialysis
device on the robotic platform. A magnetic stirrer is sunk into the platform with full manual access to the stir speed control dial. The lid of the
microdialysis device is held by the gripper arm of the robot during the loading and removal of the assembly reactions. On the left hand side, the
peristaltic pump controlling the ﬂow/dilution rate of the dialysis buﬀer can be seen. (b) Calculated urea concentration of the dilution of 200ml 6M
urea-containing buﬀer with urea-free buﬀer at a ﬂow of 1ml/min. After 17h, the urea concentration in the dialysis buﬀer has eﬀectively fallen to
zero. The change of urea concentration (dc) over time (dt) can be expressed as a diﬀerential function (dc/dt) that is equal to the dilution (-D) of the
initial concentration (c0) of urea according to the following equation ct=c0 e
 Dxt [D, Dilution (i.e. ﬂowrate/volume); ct, urea concentration at time
t; e, Euler’s constant].
250 Nucleic Acids Research, 2008, Vol. 36, No. 1device speciﬁcally for the purpose of removing a possible
source of human error (R.O.J.W., unpublished data).
Using the procedure as currently implemented it is
therefore possible to start with a bacterial expression
strain (containing a plasmid with an easily veriﬁable DNA
sequence) and to end up with a fully assembled RNAP
and an activity result within 24h. All the intermediate
steps are carried out on robotic platforms, thus essentially
eliminating the possibility of error and/or sample mix-ups.
In the worst case scenario, any unexpected or questionable
result can be easily checked by repeating the process and,
ultimately by checking the DNA sequence of the expres-
sion clone(s) used. The high degree of reproducibility and
comparability observed and documented is also due to the
fact that variants located within a single subunit (such as
the Bridge Helix mutants shown in Figure 4) are
assembled with a constant cocktail of all the other
subunits, which ensures a consistency not only within a
single experiment, but also between independent robotic
runs.
In summary, the robotic platform for the automated
puriﬁcation of mutant RNAP subunit variants, combined
with reproducible methods for assembling them into
recombinant RNAPs, provides a powerful new tool for
carrying out a detailed analysis of various functional
domains. The time-consuming nature of studying the
eﬀects of mutations in the context of multi-protein
complexes means that conventional mutagenesis studies
are typically restricted to deleting whole domains, ‘alanine
scanning’ (20), or the replacement of a small number of
key residues with a few selected substitutions. The robotic
RNA polymerase factory approach eliminates all the
bottlenecks typically encountered in the manual procedure
and thus increases experimental throughput by at least
one order of magnitude. This enhanced capacity has
encouraged us to initiate high-throughput mutagenesis
studies based on hundreds of site-speciﬁc and random
mutations in various functional domains of archaeal
RNAPs. In preliminary work, we have already obtained
several unexpected results that would probably have gone
undetected with the conventional manual approaches
(R.O.J.W. et al., unpublished observations). This shows
that this experimental strategy, although initially driven
by an assumption-free systematic mutagenesis process, has
a high degree of ‘hypothesis-generating’ potential, similar
to other current structural genomics endeavors (21).
One of the major challenges that will need to be
addressed in the foreseeable future is the development of
new types of high-throughput assays capable of analyzing
the functional properties of the large number of mutants
that can be generated by the RNAP factory approach. For
studying mutants in regions that have a direct inﬂuence on
the catalytic activity of the polymerase (such as the Bridge
Helix example described here), relatively simple assays
capable of measuring overall nucleotide incorporation can
be used to compare the activities of targeted substitutions
directly with the wild-type enzyme (Figure 4 and R.O.J.W.
et al., unpublished observations). It is, however, likely that
the full characterization of the functional properties of
mutants in other domains will depend on the development
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Figure 4. Saturation mutagenesis of mjA0-G825. (a) The sequence alignment shows part of the central and C-terminal region of the Bridge Helix
[Hs, Homo sapiens RPB1 (positions 845–863); Sc, Saccharomyces cerevisae RPB1 (positions 822–840); Mj, M. jannaschii A0 (positions 812–830)]. Bold
residues are identical in all three species and the residues orthologous to mjA0-G825 are marked by an yellow box. (b) The position of the glycine
residue in yeast RNAPII corresponding to mjA0-G825 is shown in yellow. The Bridge Helix (including the residues aligned in a) is in gray and the
backbone of the DNA template strand is shown in light blue. Note the close spatial proximity between the G825 side chain and the phosphodiester
backbone of the DNA [data from PDB #1SFO (5) visualized with Cn3D; www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml]. (c) Transcription
activity assays of RNAP variants containing all 19 possible substitutions of mjA0-G825 carried by the RNA polymerase factory. The two columns on
the right represent the positive (WT; wild-type) and negative (RNAP containing a mjA0-T821 termination codon substitution) control reactions.
Error bars shown represent standard deviations (n=4) based on independently expressed, assembled and assayed mutants carried out in parallel.
Nucleic Acids Research,2008, Vol. 36,No. 1 251of additional high-throughput assays designed to test
speciﬁc subfunctions of the enzymes (e.g. elongation rate).
Most of the currently available manual in vitro transcrip-
tion assays are gel- and autoradiography based (and thus
not suitable for implementation on robotic platforms), but
the development of new ﬂuorescence-based methodologies
(e.g.22) is likely to change this situation in the foreseeable
future. The capacity for producing large volumes of
functional data generated by such high-throughput
robotic approaches will supplement available structural
insights and may eventually need to be systematically
stored in standardized electronic formats similar to the
current literature, sequence and structural databases.
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